[
  {
    "ts": null,
    "headline": "Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know",
    "summary": "A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth",
    "url": "https://finnhub.io/api/news?id=f748b6a3dc571de13eb1fedaabf19603761a479b602748cb464eeb611f0c9cde",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755121846,
      "headline": "Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know",
      "id": 136342003,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth",
      "url": "https://finnhub.io/api/news?id=f748b6a3dc571de13eb1fedaabf19603761a479b602748cb464eeb611f0c9cde"
    }
  },
  {
    "ts": null,
    "headline": "Moderna Stock Jumps as NIH Chief Tempers Administration’s Attack on mRNA",
    "summary": "Antipathy from figures close to Trump toward mRNA technology, which underlies Moderna’s products and pipeline, has weighed on the company’s valuation.",
    "url": "https://finnhub.io/api/news?id=92c2487580647dd26791acac87419a105aaa33d306677f00cf07d2f66333122b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755112560,
      "headline": "Moderna Stock Jumps as NIH Chief Tempers Administration’s Attack on mRNA",
      "id": 136345226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Antipathy from figures close to Trump toward mRNA technology, which underlies Moderna’s products and pipeline, has weighed on the company’s valuation.",
      "url": "https://finnhub.io/api/news?id=92c2487580647dd26791acac87419a105aaa33d306677f00cf07d2f66333122b"
    }
  },
  {
    "ts": null,
    "headline": "[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
    "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global AI in Synthetic Biology Market size & share revenue was valued at approximately USD 24.58 Billion in 2024 and is expected to reach USD 30.76 Billion in 2025 and is expected to reach around USD 192.95 Billion by 2034, at a CAGR of 28.63% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Ginkgo Bioworks, Am",
    "url": "https://finnhub.io/api/news?id=a9d4b27834c4a287d359e19e4d7c32379cd4380bb80d79efec2562426598b9ab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755084600,
      "headline": "[Latest] Global AI in Synthetic Biology Market Size/Share Worth USD 192.95 Billion by 2034 at a 28.63% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)",
      "id": 136328370,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global AI in Synthetic Biology Market size & share revenue was valued at approximately USD 24.58 Billion in 2024 and is expected to reach USD 30.76 Billion in 2025 and is expected to reach around USD 192.95 Billion by 2034, at a CAGR of 28.63% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Ginkgo Bioworks, Am",
      "url": "https://finnhub.io/api/news?id=a9d4b27834c4a287d359e19e4d7c32379cd4380bb80d79efec2562426598b9ab"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Avoid MRNA and 1 Stock to Buy Instead",
    "summary": "Over the past six months, Moderna’s shares (currently trading at $25.79) have posted a disappointing 19.2% loss, well below the S&P 500’s 5.4% gain. This may have investors wondering how to approach the situation.",
    "url": "https://finnhub.io/api/news?id=eec0fae318aec301bb5de584b5c7c1f01bea541430dd1d9bb057fe852c2c4ea0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755058710,
      "headline": "3 Reasons to Avoid MRNA and 1 Stock to Buy Instead",
      "id": 136328940,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Over the past six months, Moderna’s shares (currently trading at $25.79) have posted a disappointing 19.2% loss, well below the S&P 500’s 5.4% gain. This may have investors wondering how to approach the situation.",
      "url": "https://finnhub.io/api/news?id=eec0fae318aec301bb5de584b5c7c1f01bea541430dd1d9bb057fe852c2c4ea0"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Moderna’s Q2 Earnings Call",
    "summary": "Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in year-over-year sales and ongoing operational challenges. Management attributed quarterly performance primarily to lower COVID vaccine demand and highlighted that U.S. sales performed above internal expectations due to a stronger spring booster campaign. CEO Stéphane Bancel pointed to significant cost-cutting efforts, including a 35% reduction in combined cost of sales and SG",
    "url": "https://finnhub.io/api/news?id=6949d9d0f8e6be7a524e423b46b57282bc9d8b58766bb4dddb2976ef56dd8dd3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755058516,
      "headline": "The 5 Most Interesting Analyst Questions From Moderna’s Q2 Earnings Call",
      "id": 136328941,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna’s second quarter results were met with a negative market reaction, as investors focused on both a sharp decline in year-over-year sales and ongoing operational challenges. Management attributed quarterly performance primarily to lower COVID vaccine demand and highlighted that U.S. sales performed above internal expectations due to a stronger spring booster campaign. CEO Stéphane Bancel pointed to significant cost-cutting efforts, including a 35% reduction in combined cost of sales and SG",
      "url": "https://finnhub.io/api/news?id=6949d9d0f8e6be7a524e423b46b57282bc9d8b58766bb4dddb2976ef56dd8dd3"
    }
  },
  {
    "ts": null,
    "headline": "MRNA Q2 Deep Dive: Revenue Beat Overshadowed by Lower Guidance and Cost Cuts",
    "summary": "Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year on year to $142 million. On the other hand, the company’s full-year revenue guidance of $1.85 billion at the midpoint came in 10.5% below analysts’ estimates. Its non-GAAP loss of $2.13 per share was 29% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=8bc1281ba4fe7341c9b79bba555637eb4bacf0531dcde06820409632399d3dac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755057882,
      "headline": "MRNA Q2 Deep Dive: Revenue Beat Overshadowed by Lower Guidance and Cost Cuts",
      "id": 136328942,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year on year to $142 million. On the other hand, the company’s full-year revenue guidance of $1.85 billion at the midpoint came in 10.5% below analysts’ estimates. Its non-GAAP loss of $2.13 per share was 29% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=8bc1281ba4fe7341c9b79bba555637eb4bacf0531dcde06820409632399d3dac"
    }
  }
]